HCW Biologics is developing immunotherapies to lengthen healthspan by disrupting the link between cellular senescence and disease.
HCW Biologics has raised $1.5M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in September 2026.
HCW Biologics's investors include Lee Flowers, Scott T. Garrett, DeepWork Capital, Hing C. Wong.
HCW Biologics is headquartered in Miramar Beach, United States.
HCW Biologics is developing immunotherapies to lengthen healthspan by disrupting the link between cellular senescence and disease.
HCW Biologics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"HCW Biologics — Funding & Investors." VCBacked, September 24, 2026, https://www.vcbacked.co/company/hcw-biologics. Accessed October 9, 2026.
VCBacked. (2026). HCW Biologics — Funding & Investors. Retrieved October 9, 2026, from https://www.vcbacked.co/company/hcw-biologics
{{cite web |title=HCW Biologics — Funding & Investors |url=https://www.vcbacked.co/company/hcw-biologics |website=VCBacked |access-date=October 9, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated